title: Developmental outcome at 18 and 24 months of age in very preterm children: a cohort study from 1996 to 1997.
abstract: OBJECTIVE
  To determine the effect of prematurity (gestational age (GA) < 32 weeks) on developmental outcome at the corrected age of 18 and 24 months in a regionally defined, prospective cohort study.
  
  
  METHODS
  The Leiden Follow-Up Project on Prematurity (LFUPP) includes all live-born infants < 32 weeks GA, born in 1996/1997 in three Dutch health regions (n=266). Mental and psychomotor developmental indices (MDI, PDI) were determined with the Bayley Scales of Infant Development I: > or = -1 S.D.: normal, -2 to -1 S.D.: moderate delay and < -2 S.D.: severe delay.
  
  
  RESULTS
  At 18 months 168 (71%) and at 24 months, 151 children (64%) of 235 survivors were assessed. Moderate to severely delayed mental and/or psychomotor development occurred in 40% of the children at both ages. Children lost to follow-up were of lower socioeconomic status and more frequently of non-Dutch origin. Since non-Dutch origin negatively affected the outcome at both test ages, availability of the data of these children would probably have worsened the outcome. Postnatal treatment with dexamethasone was associated with an increased risk of delayed development. Other independent predictors of delayed development were bronchopulmonary dysplasia at 18 months and ethnicity, maternal age at birth, birthweight and gender at 24 months. After adjustment for these other predictors of delayed development, the mean PDI of dexamethasone-treated infants was 16.1 points lower than of non-treated infants at 18 months (p=0.03) and 12.7 points lower at 24 months (p=0.04).
  
  
  CONCLUSIONS
  At 18 and 24 months corrected age, 40% of the very prematurely born children had both delayed mental and/or psychomotor development. Treatment with dexamethasone postnatally was a major risk factor for delayed (psychomotor) development.
authors.affiliation: Department of Pediatrics, Leiden University Medical Center, Neonatology, J6-S, PO Box 9600, Leiden 2300 RC, The Netherlands.
authors.forename: Gerlinde M S J
authors.initials: GM
authors.lastname: Stoelhorst
authors.forename: Monique
authors.initials: M
authors.lastname: Rijken
authors.forename: Shirley E
authors.initials: SE
authors.lastname: Martens
authors.forename: Paul H T
authors.initials: PH
authors.lastname: van Zwieten
authors.forename: J
authors.initials: J
authors.lastname: Feenstra
authors.forename: Aeilko H
authors.initials: AH
authors.lastname: Zwinderman
authors.forename: Jan Maarten
authors.initials: JM
authors.lastname: Wit
authors.forename: Sylvia
authors.initials: S
authors.lastname: Veen
mesh_terms: D000328:Adult; D002657:Child Development; D002658:Developmental Disabilities / Q000453:epidemiology* / Q000208:ethnology / Q000209:etiology; D003907:Dexamethasone / Q000009:adverse effects; D005260:Female; D005500:Follow-Up Studies; D005865:Gestational Age; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007234:Infant, Premature / Q000523:psychology; D008297:Male; D009426:Netherlands / Q000453:epidemiology / Q000208:ethnology; D011247:Pregnancy; D011446:Prospective Studies; D012923:Social Class
chemical_list: D003907:Dexamethasone